Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Songli Biotechnology is a Chinese regenerative medicine company focused on the development of advanced biomaterials for soft tissue repair. Utilizing a proprietary electrospinning technology platform, the company produces biomimetic scaffolds that facilitate the induction of functional tissue regeneration rather than simple mechanical support. Their flagship products include absorbable biological meshes for hernia repair and rotator cuff reinforcement, which are designed to degrade as they are replaced by the patient's own tissue. Founded in 2002, Songli is a leader in the field of degradable synthetic biomaterials in China, targeting unmet needs in surgery, orthopedics, and gynecology. The company's innovative approach aims to reduce long-term complications associated with permanent synthetic implants.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Songli Biotechnology.